Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Receivables (2021 - 2025)

Valion Bio has reported Receivables over the past 5 years, most recently at $19000.0 for Q3 2025.

  • For Q3 2025, Receivables rose 111.11% year-over-year to $19000.0; the TTM value through Sep 2025 reached $19000.0, up 111.11%, while the annual FY2024 figure was $69000.0, 60.34% down from the prior year.
  • Receivables for Q3 2025 was $19000.0 at Valion Bio, up from $13000.0 in the prior quarter.
  • Over five years, Receivables peaked at $174000.0 in Q4 2023 and troughed at $9000.0 in Q3 2024.
  • A 5-year average of $68187.5 and a median of $71500.0 in 2024 define the central range for Receivables.
  • Biggest five-year swings in Receivables: tumbled 93.13% in 2024 and later skyrocketed 111.11% in 2025.
  • Year by year, Receivables stood at $92000.0 in 2021, then rose by 16.3% to $107000.0 in 2022, then skyrocketed by 62.62% to $174000.0 in 2023, then crashed by 60.34% to $69000.0 in 2024, then plummeted by 72.46% to $19000.0 in 2025.
  • Business Quant data shows Receivables for TIVC at $19000.0 in Q3 2025, $13000.0 in Q2 2025, and $13000.0 in Q1 2025.